IL142852A0 - A COMPLEX OF A CHAPERONE WITH β-AMYLOID AND METHODS EMPLOYING THIS COMPLEX - Google Patents

A COMPLEX OF A CHAPERONE WITH β-AMYLOID AND METHODS EMPLOYING THIS COMPLEX

Info

Publication number
IL142852A0
IL142852A0 IL14285299A IL14285299A IL142852A0 IL 142852 A0 IL142852 A0 IL 142852A0 IL 14285299 A IL14285299 A IL 14285299A IL 14285299 A IL14285299 A IL 14285299A IL 142852 A0 IL142852 A0 IL 142852A0
Authority
IL
Israel
Prior art keywords
disease
complex
level
alzheimer
amyloid
Prior art date
Application number
IL14285299A
Other languages
English (en)
Original Assignee
Holtzman Jordan L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holtzman Jordan L filed Critical Holtzman Jordan L
Publication of IL142852A0 publication Critical patent/IL142852A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14285299A 1998-10-30 1999-10-29 A COMPLEX OF A CHAPERONE WITH β-AMYLOID AND METHODS EMPLOYING THIS COMPLEX IL142852A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10639898P 1998-10-30 1998-10-30
US12356499P 1999-03-10 1999-03-10
PCT/US1999/025593 WO2000026251A2 (en) 1998-10-30 1999-10-29 A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX

Publications (1)

Publication Number Publication Date
IL142852A0 true IL142852A0 (en) 2002-03-10

Family

ID=26803625

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14285299A IL142852A0 (en) 1998-10-30 1999-10-29 A COMPLEX OF A CHAPERONE WITH β-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
IL142852A IL142852A (en) 1998-10-30 2001-04-29 Complex of a chaperone q2 with beta-amyloid and methods employing this complex

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142852A IL142852A (en) 1998-10-30 2001-04-29 Complex of a chaperone q2 with beta-amyloid and methods employing this complex

Country Status (12)

Country Link
US (3) US6972318B1 (de)
EP (1) EP1125135B1 (de)
JP (1) JP4571310B2 (de)
AT (1) ATE284538T1 (de)
AU (1) AU764713B2 (de)
CA (1) CA2348545C (de)
DE (1) DE69922535T2 (de)
IL (2) IL142852A0 (de)
MX (1) MXPA01004317A (de)
NO (1) NO331974B1 (de)
NZ (1) NZ511589A (de)
WO (1) WO2000026251A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153058A0 (en) * 2000-05-24 2003-06-24 Jordan Loyal Holtzman Agents and methods for increasing brain chaperonin levels
US6962982B2 (en) 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
US7094884B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
US7094757B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
ES2294196T3 (es) * 2002-12-20 2008-04-01 F. Hoffmann-La Roche Ag Metodos para elaborar y utilizar complejos solubles de proteinas diana y chaperonas peptil prolil isomerasas.
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
JP4981305B2 (ja) * 2005-11-11 2012-07-18 公益財団法人大阪バイオサイエンス研究所 アルツハイマー病の発症リスク又はアルツハイマー病発症予後の予測方法
JP2012049495A (ja) * 2010-01-29 2012-03-08 Nitto Denko Corp 発光ダイオード装置
WO2012138284A1 (en) 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
CA2879103A1 (en) * 2012-07-13 2014-01-16 Jordan L. Holtzman Cellular and animal models for screening therapeutic agents for the treatment of alzheimer's disease
US20180099024A1 (en) * 2016-10-06 2018-04-12 Ramp Research, Llc Methods, compositions, and kits involving alteration of the chaperone protein axis in a subject

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
EP0683234B2 (de) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5707821A (en) * 1995-06-07 1998-01-13 Athena Neurosciences, Inc. Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease
JPH09178743A (ja) 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
JP2001525390A (ja) 1997-12-10 2001-12-11 エヌピーエス ファーマシューティカルズ インコーポレーテッド 抗痙攣薬および中枢神経系活性ビス（フルオロフェニル）アルキルアミド類

Also Published As

Publication number Publication date
ATE284538T1 (de) 2004-12-15
WO2000026251A3 (en) 2000-08-10
DE69922535T2 (de) 2005-05-12
IL142852A (en) 2010-05-31
NO20012114D0 (no) 2001-04-27
US7927824B2 (en) 2011-04-19
US8211658B2 (en) 2012-07-03
WO2000026251A2 (en) 2000-05-11
EP1125135A2 (de) 2001-08-22
DE69922535D1 (de) 2005-01-13
AU764713B2 (en) 2003-08-28
US6972318B1 (en) 2005-12-06
JP2002528555A (ja) 2002-09-03
CA2348545C (en) 2012-08-21
EP1125135B1 (de) 2004-12-08
NO20012114L (no) 2001-06-14
NZ511589A (en) 2005-02-25
AU1810500A (en) 2000-05-22
CA2348545A1 (en) 2000-05-11
NO331974B1 (no) 2012-05-14
JP4571310B2 (ja) 2010-10-27
US20060024759A1 (en) 2006-02-02
MXPA01004317A (es) 2003-06-06
US20110256569A1 (en) 2011-10-20
WO2000026251A9 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
IL142852A0 (en) A COMPLEX OF A CHAPERONE WITH β-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
Schwimmer et al. Histopathology of pediatric nonalcoholic fatty liver disease
Schmidt et al. White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease
Pezzilli et al. Mutations of the CFTR gene in pancreatic disease
El-Mezayen et al. Diagnostic performance of collagen IV and laminin for the prediction of fibrosis and cirrhosis in chronic hepatitis C patients: a multicenter study
Giannelli et al. SCCA antigen combined with alpha‐fetoprotein as serologic markers of HCC
EP0792458A4 (de) Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x- 41) und tau
BR9916407A (pt) Detecção e tratamento de doenças dos rins
GB0512401D0 (en) Method
DE60331941D1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
DE69941627D1 (de) Für krebs
Weiler et al. Genetic test indications and interpretations in patients with hereditary angioedema
KR102591417B1 (ko) 대변 모니터링 및 건강 지도 장치
Świderska et al. Serum cytokeratin 18 M30 levels in chronic hepatitis B reflect both phase and histological activities of disease
Lanzrein et al. Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer's disease
ATE139803T1 (de) Allelische verbindung des humanen dopamin- (d2)rezeptor-gens in kompulsionsstörungen wie alkoholismus
Osuna et al. Vitreous humor carbohydrate-deficient transferrin concentrations in the postmortem diagnosis of alcoholism
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
Su et al. Two novel mutations in the gene encoding thyroxine‐binding globulin (TBG) as a cause of complete TBG deficiency in Taiwan
Cadranel et al. Prothrombin index decrease: a useful and reliable marker of extensive fibrosis?
FI990380A0 (fi) Diagnostinen ja seulontamenetelmä
DE60012688D1 (de) Immunoassays zum nachweis von krankheiten oder krankheitsanfälligkeitsmerkmalen
AU2003233292A8 (en) Protein c polymorphisms
Roberts et al. Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD
TW200517502A (en) Methods for detecting Alzheimer's disease